Martin Babler, Alumis CEO

Alu­mis aims for this year’s third-largest biotech IPO as it read­ies for Phase 3

Clin­i­cal-stage im­munol­o­gy biotech Alu­mis is eye­ing $274 mil­lion in net pro­ceeds from its planned ini­tial pub­lic of­fer­ing, the biotech said in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.